Published in AIDS Weekly, April 8th, 2002
"The initiation of this phase II trial and the initial dosing of patients is a significant milestone for us," said Dr. Benjamin Corn, Keryx Biopharmaceuticals' president and CEO. "We feel this is an important step in Keryx's ongoing efforts to provide an effective...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.